ALTH » Topics » If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.

This excerpt taken from the ALTH 10-K filed Mar 1, 2010.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of FOLOTYN or otherwise be subject to unfavorable terms.

        Any future strategic partnerships we enter into could subject us to a number of risks, including:

    we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

    we may be required to issue equity securities that would dilute our existing stockholders' percentage ownership;

    we may be required to assume substantial actual or contingent liabilities;

    we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of FOLOTYN;

    strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

    strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

    strategic partners may not commit adequate resources to the marketing and distribution of FOLOTYN or any other products, limiting our potential revenues from these products;

    disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of FOLOTYN or any other product candidate or that result in costly litigation or arbitration that diverts management's attention and consumes resources;

    strategic partners may experience financial difficulties;

    strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

    business combinations or significant changes in a strategic partner's business strategy may also adversely affect a strategic partner's willingness or ability to complete its obligations under any arrangement;

    strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

    strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing FOLOTYN or any other product candidate.

36


Table of Contents

This excerpt taken from the ALTH 10-Q filed May 5, 2009.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of pralatrexate or otherwise be subject to unfavorable terms.

 

Any future strategic partnerships we enter into could subject us to a number of risks, including:

 

·                  we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

 

·                  we may be required to issue equity securities that would dilute our existing stockholders’ percentage ownership;

 

·                  we may be required to assume substantial actual or contingent liabilities;

 

·                  we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of pralatrexate;

 

·                  strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

 

·                  strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

 

·                  strategic partners may not commit adequate resources to the marketing and distribution of pralatrexate or any other products, limiting our potential revenues from these products;

 

·                  disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of pralatrexate or any other product candidate or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;

 

·                  strategic partners may experience financial difficulties;

 

·                  strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

 

·                  business combinations or significant changes in a strategic partner’s business strategy may also adversely affect a strategic partner’s willingness or ability to complete its obligations under any arrangement;

 

·                  strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

 

·                  strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing pralatrexate or any other product candidate.

 

29



These excerpts taken from the ALTH 10-K filed Mar 3, 2009.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of pralatrexate or otherwise be subject to unfavorable terms.

        Any future strategic partnerships we enter into could subject us to a number of risks, including:

    we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

    we may be required to issue equity securities that would dilute our existing stockholders' percentage ownership;

    we may be required to assume substantial actual or contingent liabilities;

    we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of pralatrexate;

    strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

    strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

    strategic partners may not commit adequate resources to the marketing and distribution of pralatrexate or any other products, limiting our potential revenues from these products;

    disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of pralatrexate or any other product candidate or that result in costly litigation or arbitration that diverts management's attention and consumes resources;

    strategic partners may experience financial difficulties;

    strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

    business combinations or significant changes in a strategic partner's business strategy may also adversely affect a strategic partner's willingness or ability to complete its obligations under any arrangement;

    strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

    strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing pralatrexate or any other product candidate.

27


Table of Contents

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of pralatrexate or otherwise be
subject to unfavorable terms.



        Any future strategic partnerships we enter into could subject us to a number of risks, including:





    we may be required to undertake the expenditure of substantial operational, financial and management resources in
    integrating new businesses, technologies and products;



    we may be required to issue equity securities that would dilute our existing stockholders' percentage ownership;


    we may be required to assume substantial actual or contingent liabilities;


    we may not be able to control the amount and timing of resources that our strategic partners devote to the development or
    commercialization of pralatrexate;



    strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a
    product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;



    strategic partners may not pursue further development and commercialization of products resulting from the strategic
    partnering arrangement or may elect to discontinue research and development programs;



    strategic partners may not commit adequate resources to the marketing and distribution of pralatrexate or any other
    products, limiting our potential revenues from these products;



    disputes may arise between us and our strategic partners that result in the delay or termination of the research,
    development or commercialization of pralatrexate or any other product candidate or that result in costly litigation or arbitration that diverts management's attention and consumes resources;



    strategic partners may experience financial difficulties;


    strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary
    information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;



    business combinations or significant changes in a strategic partner's business strategy may also adversely affect a
    strategic partner's willingness or ability to complete its obligations under any arrangement;



    strategic partners could independently move forward with a competing product candidate developed either independently or
    in collaboration with others, including our competitors; and



    strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may
    increase the cost of developing pralatrexate or any other product candidate.


27













NAME="page_dg12401_1_28">








































Table of Contents



This excerpt taken from the ALTH 10-Q filed Nov 5, 2008.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.

 

Any future strategic partnerships we enter into could subject us to a number of risks, including:

 

·                  we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

 

·                  we may be required to issue equity securities that would dilute our existing stockholders’ percentage ownership;

 

·                  we may be required to assume substantial actual or contingent liabilities;

 

·                  we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;

 

·                  strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

 

·                  strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

 

·                  strategic partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;

 

·                  disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;

 

·                  strategic partners may experience financial difficulties;

 

·                  strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

 

31



Table of Contents

 

·                  business combinations or significant changes in a strategic partner’s business strategy may also adversely affect a strategic partner’s willingness or ability to complete its obligations under any arrangement;

 

·                  strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

 

·                  strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.

 

This excerpt taken from the ALTH 10-Q filed Aug 5, 2008.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.

 

Any future strategic partnerships we enter into could subject us to a number of risks, including:

 

·                  we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

 

·                  we may be required to issue equity securities that would dilute our existing stockholders’ percentage ownership;

 

·                  we may be required to assume substantial actual or contingent liabilities;

 

·                  we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;

 

·                  strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

 

·                  strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

 

·                  strategic partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;

 

·                  disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;

 

·                  strategic partners may experience financial difficulties;

 

·                  strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

 

·                  business combinations or significant changes in a strategic partner’s business strategy may also adversely affect a strategic partner’s willingness or ability to complete its obligations under any arrangement;

 

·                  strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

 

·                  strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.

 

This excerpt taken from the ALTH 10-Q filed May 7, 2008.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.

 

Any future strategic partnerships we enter into could subject us to a number of risks, including:

 

·                  we may be required to undertake the expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

 

·                  we may be required to issue equity securities that would dilute our existing stockholders’ percentage ownership;

 

·                  we may be required to assume substantial actual or contingent liabilities;

 

·                  we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;

 

·                  strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

 

·                  strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

 

·                  strategic partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;

 

·                  disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;

 

·                  strategic partners may experience financial difficulties;

 

·                  strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

 

·                  business combinations or significant changes in a strategic partner’s business strategy may also adversely affect a strategic partner’s willingness or ability to complete its obligations under any arrangement;

 

·                  strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

 

·                  strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.

 

27



 

These excerpts taken from the ALTH 10-K filed Feb 27, 2008.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or otherwise be subject to unfavorable terms.

        Any future strategic partnerships we enter into could subject us to a number of risks, including:

    we may be required to undertake expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;

    we may be required to issue equity securities that would dilute our existing stockholders' percentage ownership;

    we may be required to assume substantial actual or contingent liabilities;

    we may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;

    strategic partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;

    strategic partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue research and development programs;

    strategic partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;

    disputes may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management's attention and consumes resources;

    strategic partners may experience financial difficulties;

25


    strategic partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

    business combinations or significant changes in a strategic partner's business strategy may also adversely affect a strategic partner's willingness or ability to complete its obligations under any arrangement;

    strategic partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and

    strategic partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.

If we enter into one or more strategic partnerships, we may be required to relinquish important rights to and control over the development of our product candidates or
otherwise be subject to unfavorable terms.



        Any future strategic partnerships we enter into could subject us to a number of risks, including:





    we
    may be required to undertake expenditure of substantial operational, financial and management resources in integrating new businesses, technologies and products;


    we
    may be required to issue equity securities that would dilute our existing stockholders' percentage ownership;


    we
    may be required to assume substantial actual or contingent liabilities;


    we
    may not be able to control the amount and timing of resources that our strategic partners devote to the development or commercialization of product candidates;


    strategic
    partners may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials
    or require a new version of a product candidate for clinical testing;


    strategic
    partners may not pursue further development and commercialization of products resulting from the strategic partnering arrangement or may elect to discontinue
    research and development programs;


    strategic
    partners may not commit adequate resources to the marketing and distribution of any future products, limiting our potential revenues from these products;


    disputes
    may arise between us and our strategic partners that result in the delay or termination of the research, development or commercialization of our product candidates
    or that result in costly litigation or arbitration that diverts management's attention and consumes resources;


    strategic
    partners may experience financial difficulties;


25












    strategic
    partners may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or
    invalidate our proprietary information or expose us to potential litigation;


    business
    combinations or significant changes in a strategic partner's business strategy may also adversely affect a strategic partner's willingness or ability to complete
    its obligations under any arrangement;


    strategic
    partners could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our
    competitors; and


    strategic
    partners could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki